Atlas Trials

LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

Clinical trial NCT07737925 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07737925
Sponsor
Thomas Jefferson University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate CancerMetastatic Castrate Resistant Prostate Cancer
Start date
2026-10-01
Primary completion
2030-10-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.